Synthesis and biological evaluation of SGLT2 inhibitors: gem-difluoromethylenated Dapagliflozin analogs

被引：19
|
作者：
Chen, Zeng-Hao [1 ]
Wang, Ruo-Wen [1 ]
Qing, Feng-Ling [1 ,2 ]
机构：
[1] Chinese Acad Sci, Shanghai Inst Organ Chem, Key Lab Organofluorine Chem, Shanghai 200032, Peoples R China
[2] Donghua Univ, Coll Chem Chem Engn & Biotechnol, Shanghai 201620, Peoples R China
来源：
TETRAHEDRON LETTERS | 2012年 / 53卷 / 17期
基金：
中国国家自然科学基金;
关键词：
Dapagliflozin; SGLT2; inhibitor; Difluoromethylene; Diabetes; GLUCOSE; DISCOVERY; POTENT; ROUTE;
D O I：
10.1016/j.tetlet.2012.02.062
中图分类号：
O62 [有机化学];
学科分类号：
070303 ; 081704 ;
摘要：
Dapagliflozin is currently the most advanced SGLT2 inhibitor, which has been used in Phase III clinical trials for treatment of diabetes. Here we describe the design and synthesis of Dapagliflozin analogs modified with gem-difluoromethylene group. Their biological evaluation of in vitro inhibitory activity against human SGLT2 showed that some of the analogs with CF2 at C-4 are better SGLT2 inhibitors compared with Dapagliflozin. (c) 2012 Elsevier Ltd. All rights reserved.
引用
收藏
页码：2171 / 2176
页数：6
相关论文
共 50 条
  • [41] Facile synthesis of 1,2,3-triazole analogs of SGLT2 inhibitors by 'click chemistry'
    Li, Lan-Tao
    Zhou, Li-Fei
    Li, Yan-Jun
    Huang, Juan
    Liu, Rui-Hua
    Wang, Bin
    Wang, Peng
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2012, 22 (01) : 642 - 644
  • [42] Acute antiarrhythmic effects of SGLT2 inhibitors–dapagliflozin lowers the excitability of atrial cardiomyocytes
    Amelie Paasche
    Felix Wiedmann
    Manuel Kraft
    Fitzwilliam Seibertz
    Valerie Herlt
    Pablo L. Blochberger
    Natasa Jávorszky
    Moritz Beck
    Leo Weirauch
    Timon Seeger
    Antje Blank
    Walter E. Haefeli
    Rawa Arif
    Anna L. Meyer
    Gregor Warnecke
    Matthias Karck
    Niels Voigt
    Norbert Frey
    Constanze Schmidt
    Basic Research in Cardiology, 2024, 119 : 93 - 112
  • [43] Synthesis of gem-Difluoromethylenated Spiro-γ-butyrolactones by Employing PhSCF2Si(CH3)3 as a gem-Difluoromethylenating Agent
    Chatupheeraphat, Adisak
    Soorukram, Darunee
    Kuhakarn, Chutima
    Tuchinda, Patoomratana
    Reutrakul, Vichai
    Pakawatchai, Chaveng
    Saithong, Saowanit
    Pohmakotr, Manat
    EUROPEAN JOURNAL OF ORGANIC CHEMISTRY, 2013, 2013 (30) : 6844 - 6858
  • [44] Ketoacidosis with SGLT2 Inhibitors
    不详
    MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2015, 57 (1471): : 94 - 94
  • [45] SGLT2 inhibitors and cardioprotection
    Chen, S.
    Wang, Q.
    Christodoulou, A.
    Mylonos, N.
    Bakker, D.
    Wakker, V.
    Hollmann, M. W.
    Weber, N. C.
    Coronel, R.
    Christoffels, V.
    Andreadou, I.
    Zuurbier, C. J.
    EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2023, 53
  • [46] Synthesis and biological evaluation of novel tetrahydroisoquinoline-C-aryl glucosides as SGLT2 inhibitors for the treatment of type 2 diabetes
    Pan, Xuan
    Huan, Yi
    Shen, Zhufang
    Liu, Zhanzhu
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2016, 114 : 89 - 100
  • [47] SGLT2 inhibitors: are they safe?
    Filippas-Ntekouan, Sebastian
    Filippatos, Theodosios D.
    Elisaf, Moses S.
    POSTGRADUATE MEDICINE, 2018, 130 (01) : 72 - 82
  • [48] Synthesis of gem-Difluoromethylenated Compounds Employing α,α-Difluoro-α-phenylsulfanyl-α-trimethylsilylmethane (PhSCF2SiMe3) as a gem-Difluoromethylene Building Block
    Soorukram, Darunee
    Kuhakarn, Chutima
    Reutrakul, Vichai
    Pohmakotr, Manat
    SYNLETT, 2014, 25 (18) : 2558 - 2573
  • [49] Dapagliflozin. SGLT2 inhibitor, Antidiabetic agent
    Cole, P.
    Vicente, M.
    Castaner, R.
    DRUGS OF THE FUTURE, 2008, 33 (09) : 745 - 751
  • [50] DAPAGLIFLOZIN, AN SGLT2 INHIBITOR FOR THE TREATMENT OF TYPE 2 DIABETES
    Demaris, K. M.
    White, J. R.
    DRUGS OF TODAY, 2013, 49 (05) : 289 - 301
12345